Details of the Drug

General Information of Drug (ID: DM71I53)

• Drug Name: APC-100

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1/2	[1]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 220.31
  Logarithm of the Partition Coefficient (xlogp); 3.6
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• Chemical Identifiers:
  Formula: C14H20O2
  IUPAC Name: 2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-ol
  Canonical SMILES: CC1=C(C2=C(CCC(O2)(C)C)C(=C1O)C)C
  InChI: InChI=1S/C14H20O2/c1-8-9(2)13-11(10(3)12(8)15)6-7-14(4,5)16-13/h15H,6-7H2,1-5H3
  InChIKey: SEBPXHSZHLFWRL-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 99479
  CAS Number: 950-99-2
  UNII: 7G73627R36
  DrugBank ID: DB13111
  TTD ID: D0N7DQ
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Inhibitor	[1]

Molecular Expression Atlas of This Drug

• The Studied Disease: Prostate cancer
• ICD Disease Classification: 2C82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11

References

• [1] 2011 Pipeline of Adamis Pharmaceuticals.